Koskenvuo Laura, Paajanen Paavo, Varpe Pirita, Seppälä Toni, Mentula Panu, Haapamäki Carola, Carpelan-Holmström Monika, Carpelan Anu, Lehto Kirsi, Satokari Reetta, Lepistö Anna, Sallinen Ville
Gastroenterological Surgery, HUS Helsinki University Hospital, Helsinki, Finland
Gastroenterological Surgery, HUS Helsinki University Hospital, Helsinki, Finland.
BMJ Open. 2025 May 6;15(5):e096091. doi: 10.1136/bmjopen-2024-096091.
Loop ileostomy and loop colostomy are both used to form a protective stoma after anterior resection. Evidence regarding which of these two procedures is superior is lacking. Furthermore, no studies comparing changes in the microbiome after loop ileostomy or loop colostomy exist.
This multicentre, open-label, superiority, individually randomised controlled trial will include patients who undergo anterior rectal resection with primary anastomosis with a protective stoma. The exclusion criteria are patients who already have a stoma, technical inability to create either type of stoma, aged <18 years and inadequate cooperation. Patients scheduled for anterior rectal resection will be randomised intraoperatively in a 1:1 ratio to undergo either loop ileostomy or loop colostomy. The primary outcome is cumulative stoma-related adverse events within 60 days after primary surgery, measured using the Comprehensive Complication Index (CCI). Secondary outcomes include all postoperative complications (measured using the CCI), number of hospital-free days within 30 days after primary surgery, quality of life at 2 months (measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires-Core 30 and Colorectal 29), complications within 30 days after stoma closure (measured using the CCI) and kidney function (measured using estimated glomerular filtration rate) at 1 year. Tertiary outcomes are survival, kidney function and number of stoma site hernias at 5 years. The sample size was calculated to detect a mean difference of five CCI points between groups, resulting in a final sample size of 350 patients. Microbiome samples will be collected from the faeces and mucous membrane from patients in Helsinki University Hospital.
The Ethics Committee of Helsinki University Hospital approved the study (approval number 4579/2024). The findings will be disseminated in peer-reviewed academic journals.
ClinicalTrials.gov, NCT06650085, registered on 20 August 2024.
Version 3.0, dated 17 April 2025.
回肠袢式造口术和结肠袢式造口术均用于前切除术之后形成保护性造口。目前缺乏关于这两种手术哪种更具优势的证据。此外,尚无研究比较回肠袢式造口术或结肠袢式造口术后微生物群的变化。
这项多中心、开放标签、优效性、个体随机对照试验将纳入接受直肠前切除术并进行一期吻合术及保护性造口的患者。排除标准为已存在造口的患者、技术上无法创建任何一种造口的患者、年龄<18岁以及合作不佳的患者。计划接受直肠前切除术的患者将在术中按1:1的比例随机分组,分别接受回肠袢式造口术或结肠袢式造口术。主要结局是初次手术后60天内累积的造口相关不良事件,采用综合并发症指数(CCI)进行测量。次要结局包括所有术后并发症(采用CCI测量)、初次手术后30天内的无住院天数、术后2个月的生活质量(采用欧洲癌症研究与治疗组织生活质量问卷核心30项和结直肠癌29项进行测量)、造口关闭后30天内的并发症(采用CCI测量)以及术后1年的肾功能(采用估计肾小球滤过率测量)。三级结局是5年时的生存率、肾功能和造口部位疝的数量。计算得出样本量,以检测两组之间CCI平均相差5分,最终样本量为350例患者。将从赫尔辛基大学医院患者的粪便和黏膜中收集微生物群样本。
赫尔辛基大学医院伦理委员会批准了该研究(批准号4579/2024)。研究结果将在同行评审的学术期刊上发表。
ClinicalTrials.gov,NCT06650085,于2024年8月20日注册。
2025年4月17日的第3.0版。